YIH
ALBO

Y-Intercept (HK)’s Albireo Pharma Inc ALBO Stock Holding History

Y-Intercept (HK)’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10,010
Closed -$194K – 1451
2022
Q3 		$194K Buy
+10,010
New +$207K 0.02% 828

Other funds holding ALBO

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

Y-Intercept (HK)'s ALBO Position: Q4 2022 in Review

Y-Intercept (HK) sold out of Albireo Pharma Inc (ALBO) in Q4 2022, closing a stake of 10,010 shares — an estimated $194K sold.

Y-Intercept (HK) first reported a position in ALBO in Q3 2022 and held it in 1 quarter. The position peaked at $194K in Q3 2022. 96 funds tracked by Wall St. Rank hold ALBO as of Q4 2022.

  • Y-Intercept (HK) reported no remaining Albireo Pharma Inc position as of Q4 2022 after selling out during the quarter.
  • Y-Intercept (HK) sold 10,010 Albireo Pharma Inc shares in Q4 2022, an estimated $194K.
  • Y-Intercept (HK) first reported a position in Albireo Pharma Inc in Q3 2022 and held it in 1 quarter.
  • Y-Intercept (HK)'s Albireo Pharma Inc position peaked at $194K in Q3 2022.
  • 96 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q4 2022.

Based on Y-Intercept (HK)'s 13F filing for Q4 2022, filed 14 Feb 2023.